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Abstract  
Epstein–Barr virus (EBV) was the first tumor virus identified in humans. It is primarily associated 
with lymphomas and epithelial cell cancers. These tumors express latent EBV antigens and the 
oncogenic potential of individual latent EBV proteins has been extensively explored. 
Nevertheless, it was presumed that the pro-proliferative and anti-apoptotic functions of these 
oncogenes allow the virus to persist in humans; however, recent evidence suggests that cellular 
transformation is not required for virus maintenance. Vice versa, lytic EBV replication was 
assumed to destroy latently infected cells and thereby inhibit tumorigenesis, but at least the 
initiation of the lytic cycle has now been shown to support EBV-driven malignancies. In addition 
to these changes in the roles of latent and lytic EBV proteins during tumourigenesis, the function 
of non-translated RNAs has become clearer, suggesting that they might mainly mediate immune 
escape rather than cellular transformation. In this Review, these recent findings will be 
discussed with respect to the role of EBV-encoded oncogenes in viral persistence and the 
contributions of lytic replication as well as non-translated RNAs in virus-driven tumor formation. 
Accordingly, early lytic EBV antigens and attenuated viruses without oncogenes and miRNAs 
could be harnessed for immunotherapies and vaccination. 
 
Table of contents blurb (40–50 words max.) 
Epstein–Barr virus (EBV) establishes latent and persistent infections in humans, and is 
associated with several cancers. In this Review, Münz discusses the evidence for EBV 
persistence without B cell transformation and the role of early abortive lytic replication, as well 
as non-translated RNAs in EBV-driven tumourigenesis.   
Christian Münz  3 
 
Introduction  
Epstein–Barr virus (EBV; also known as human herpesvirus 4 (HHV4)) is a large double-
stranded DNA virus that belongs to the -herpesviridae subfamily1. It was originally identified in 
1964 by Sir Anthony Epstein and co-workers in Burkitt’s lymphoma which is still the most 
common childhood tumor in Sub-Saharan Africa2,3. EBV is also the most growth transforming 
and the most widely distributed human pathogen. It can readily transform human B cells into 
indefinitely growing lymphoblastoid cell lines (LCLs) in the culture dish4,5. Despite this high 
tumorigenic potential (Box 1), the vast majority of the >95% of the human adult population that 
carry EBV as a persistent infection never develop EBV-associated malignancies6. EBV research 
has been driven by this fascinating conundrum ever since its discovery.  
 EBV is transferred via saliva exchange, and therefore symptomatic primary infection or 
infectious mononucleosis was referred to as ‘kissing disease’ in the Anglo-Saxon world7. In 
submucosal secondary lymphoid tissues like the tonsils, the virus infects its primary host target 
cell — the human B cell — by binding to complement receptors 1 and 2 as well as MHC class II 
as a co-receptor8,9. How the virus is transferred across the mucosal epithelium that separates 
saliva from secondary lymphoid tissues remains unclear, despite the fact that EBV-associated 
carcinomas (for example, nasopharyngeal carcinoma and the ~10% EBV-positive gastric 
carcinomas) clearly indicate that EBV can infect epithelial cells10. However, polarized epithelia 
cannot be infected with virus particles from the apical surface that lines the oropharynx11. 
Moreover, virus seems to appear in blood B cells earlier than detectable shedding into the 
saliva, possibly from epithelial cells12. Furthermore, the epigenetic modifications that render the 
viral genome susceptible for the induction of lytic replication after it circularizes into an episome 
in the nucleus of infected cells seems to take approximately two weeks in B cells13, raising the 
possibility that the virus infection would be stuck in the rapidly turning over mucosal epithelium 
before it could be shed into the submucosal secondary lymphoid tissues. Importantly, this 
epigenetic modification might strongly depend on the cellular context. Lytic cycle reactivation 
might be less dependent on DNA methylation in epithelial cells and this epigenetic modification 
of the viral genome could also differ in its kinetics from B cells in this cell type14-17. Nevertheless, 
transcytosis of EBV across polarized oral epithelia cell cultures has been demonstrated18. 
These considerations suggest that infectious EBV particles are transported across mucosal 
epithelia to infect B cells first. 
 In B cells, EBV persists by B cell transformation into immortalized proliferating LCLs in 
vitro and by establishing latency with only non-translated RNA expression from the viral DNA in 
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memory B cells in vivo8,19. The eight viral proteins that are expressed in LCLs in addition to the 
non-translated RNAs that are found during persistence in memory B cells were named the latent 
EBV proteins and primarily studied in the context of EBV-driven oncogenesis20. Based on the 
detection of intermediate expression levels of only three latent EBV proteins during the B cell 
differentiation stage of germinal center B cells that could result from naïve B cells after their 
activation by the eight latent EBV proteins and precede memory B cell development21, it was 
suggested that the virus induces oncogenesis to drive infected B cells into differentiation in 
order to gain access to the memory B cell pool for persistence. However, recent evidence 
suggests that expression of all eight latent EBV proteins and B cell transformation by these 
proteins might not be required for EBV persistence and latency22. Furthermore, not only these 
eight latent EBV proteins, but also early lytic EBV proteins could enhance viral oncogenesis23.  
In this Review, I will discuss the evidence for EBV persistence without B cell 
transformation and the role of early abortive lytic replication as well as non-translated RNAs in 
EBV-driven tumor formation. These are timely topics as the field gears up to develop an EBV-
specific vaccine and the identity of the infection programs and their antigens that should be 
targeted is hotly debated. Moreover, attenuated viruses, including virus-like particles, are 
considered as vaccine candidates24, but the new roles of viral oncogenes in persistence, and of 
lytic EBV antigens and non-translated RNAs in tumorigenesis could also point towards 
attenuated viruses without the respective genes as viable vaccine candidates. 
 
Epstein–Barr virus replication 
EBV can replicate by two means — vertical B cell proliferation or lytic virion production. Latent 
EBV proteins stimulate host cell proliferation and EBV DNA replicates within these cells. 
Alternatively, EBV can produce infectious virions during lytic replication; however, the latter 
might be mainly required for transmission, whereas latent infection is the default program of 
infection in B cells and could spread EBV in the infected host. Within tonsillar B cells, latent EBV 
protein encoding genes are predominantly expressed and cause activation, proliferation and 
resistance to cell death. These genes of the latent EBV infection encode 8 EBV proteins, 2 
Epstein–Barr virus encoded small RNAs (EBERs) that are not translated and 25 pre-miRNAs 
that give rise to at least 44 miRNAs20,25. All of these can be found in LCLs, naïve tonsillar B cells 
of healthy virus carriers and nearly all tonsillar B cells of individuals with infectious 
mononucleosis21,26,27 (Figure 1). The respective viral gene expression program is called latency 
III. Presumably after activation from EBV latency III, B cells enter the germinal center reaction 
and only 3 latent EBV proteins can be found in centroblasts and centrocytes21. These are 
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Epstein–Barr nuclear antigen 1 (EBNA1) and the two latent membrane proteins (LMP1 and 
LMP2). Their expression in the so-called latency IIa program is thought to ensure that EBV-
infected B cells survive the germinal center reaction to gain access to the memory B cell pool, in 
which EBV persists without viral protein expression in latency 019. Only during homeostatic 
proliferation is EBNA1transiently expressed in memory B cells, and this pattern is called latency 
I28. These latent EBV infection programs in B cells of healthy virus carriers represent the 
premalignant states of EBV-associated B cell lymphomas. Accordingly, Burkitt’s lymphoma 
expresses latency I, Hodgkin’s lymphoma expresses latency IIa and some, but not all diffuse 
large B cell lymphomas express latency III6,10. EBV replicates in latency I, II and III via the 
proliferation of activated B cells. Only from latency 0 and I, and after extensive methylation of 
the viral genome, can lytic replication with its expression of >80 viral genes be efficiently 
induced, because the immediate early transcription factor BZLF1 that cooperates with the 
BRLF1 transcription factor to initiate infectious particle production prefers methylated CpG 
sequences13,15. It is thought that stimulation of the B cell receptor of EBV-infected B cells 
expressing latency 0 or I programs leads to lytic reactivation29. The resulting plasma cell 
differentiation stimulates BZLF1 expression via the plasma cell-associated transcription factors 
XBP1 and BLIMP130,31 (Figure 1). Lytic EBV gene products then further stimulate plasma cell 
differentiation with B cell receptor down-regulation and complement secretion32. In healthy EBV 
carriers, lytic replication is found in plasma cells only33. Basolateral infection of mucosal 
epithelial cells by plasma cell-released virus might lead to an additional replication round for 
more efficient EBV shedding into the saliva. This epithelial cell infection presumably occurs via 
virus binding to v integrins and the ephrin A2 receptor34-36. Terminal epithelial cell 
differentiation has also been shown to trigger lytic replication via BLIMP1-mediated BZLF1 
expression31. Furthermore, during uncontrolled lytic EBV replication in the tongue epithelium (a 
condition called oral hairy leukoplakia), EBV replication could only be found in BLIMP1-positive 
cells 37. Thus, most of the EBV life cycle in healthy EBV carriers is confined to B cells, in which 
the virus establishes premalignant latent gene expression patterns that are also found in EBV-
associated lymphomas. 
 
Transformation and oncogenesis 
EBV infection is sufficient to transform human B cells in cell culture. The resulting LCLs 
resemble EBV-associated B cell lymphomas that develop under immune suppression, for 
example,  during HIV-1 co-infection, due to old age or after iatrogenic immune suppression 
during transplantation6. In addition, EBV infection is thought to drive infected B cells through 
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their activation into the germinal center reaction, where additional mutations can arise via the 
machinery that diversifies the B cell receptor in this reaction. Some of these somatic mutations 
substitute for the down-regulation of some of the latent EBV antigens in tumors like Hodgkin’s 
and Burkitt’s lymphoma6.  
 What are the functions of the respective EBV gene products that give the virus its 
oncogenic abilities? Many of the respective proteins (for example, the six nuclear antigens or 
EBNAs and the two membrane proteins or LMPs), are like Swiss Army Knives with many 
functions. Therefore, I will only highlight their main effects during B cell transformation, which 
has been suggested to result from the desire of the virus to activate and differentiate host cells 
into long-lived memory B cells. The EBNA1 protein is required to initiate viral genome replication 
during latent infection prior to mitosis and then it anchors the viral episomes to condensed host 
chromatin during cell division for correct distribution of the 10–40 viral genomes per infected B 
cell to the daughter cells38. However, its host chromatin binding activity also mediates some 
growth transforming activity39. Accordingly, EBNA1 expression in murine B cells induces tumors 
with some similarities to Burkitt’s lymphoma40. EBNA2 induces the transcription of the cellular 
oncogene MYC and compromises lytic EBV replication by inducing Tet methylcytosine 
dioxygenase 2 (TET2) expression, thereby blocking methylation sites for BZLF1 binding16,17,41. 
The EBNA leader peptide (EBNA-LP) cooperates with EBNA2 for viral oncogene, like LMP1, 
expression42. EBNA3A and EBNA3C rescue infected cells that are driven into a proliferative 
state by EBNA2-dependent MYC expression via the down-regulation of the proapoptotic BIM 
and p16INK4a proteins that respond to the hyperproliferation of the infected cells43. Furthermore, 
they prevent transition into lytic replication by suppression of BLIMP1 expression44. By contrast, 
EBNA3B ensures sufficient immune cell infiltration between EBV transformed B cells to restrict 
these to a level that most EBV carriers do not develop lymphomas45. The two latent membrane 
proteins replace signals that are required for EBV transformed B cells to survive the germinal 
center reaction46. LMP2 signals constitutively, similar to the B cell receptor, which needs to be 
engaged by antigen on follicular dendritic cells as signal 1 in order for germinal center B cells to 
not undergo apoptosis47. When expressed in murine B cells, LMP2 can even replace the B cell 
receptor and B cells that inactivate their receptor through somatic hypermutation can still 
survive48. Thus, LMP2 provides a strong survival signal for B cells. By contrast, LMP1 mimics 
CD4+ T helper cells in the germinal center by constitutively signaling in a manner similar to 
CD40 that is engaged by these helper T cells via their CD40 ligand49. Expressing LMP1 in 
murine B cells leads to aggressive lymphomagenesis50,51. The germinal center differentiation of 
EBV-infected B cells also leads them into a dangerous environment for the acquisition of 
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additional, growth transforming mutations. Indeed the translocation of MYC into the B cell 
receptor loci, a hallmark of Burkitt’s lymphoma, seems to originate from germinal centers and is 
likely initiated by activation induced deaminase (AID), an enzyme that is expressed at these 
sites for B cell receptor diversification52,53. Thus, EBV encodes at least two sets of proteins that 
combine pro-proliferative and anti-apoptotic functions (pro-proliferative EBNA2 plus anti-
apoptotic EBNA3A and EBNA 3C; and pro-proliferative LMP1 and anti-apoptotic LMP1 and 
LMP2). The classical view has been that these latent EBV proteins are necessary and sufficient 
for both tumor formation and activation of infected B cells to drive their differentiation into the 
long-lived memory B cell pool of EBV persistence. In the following sections, I will discuss how 
the sequential expression of the protein groups of latency III might allow latency 0 to branch off 
prior to full transformation for an alternative pathway to EBV persistence, and how lytic EBV 
replication and the viral non-translated RNAs contribute to viral oncogenesis. These new 
models could explain recent studies that demonstrate persistence without prior establishment of 
latency III and decreased EBV-driven tumor formation without lytic EBV protein and EBV miRNA 
expression. 
 
Persistence without transformation  
The above linear differentiation model from latency III to II and then to latency 0 or I is also 
called the germinal center model of EBV persistence20. It was originally proposed on the basis 
of successive down-regulation of latent EBV protein expression along the path of B cell 
differentiation, suggesting that EBV drives this differentiation through its oncogenes21. By 
contrast, persistence without transformation suggests that EBV can reach the memory B cell 
pool without latency III protein expression as a prerequisite, and outside of the germinal center. 
Indeed, even under conditions in which germinal centers are disorganized, like during infectious 
mononucleosis26, latency 0 expressing B cells start circulating in the peripheral blood pool54. It 
was postulated that massive clonal expansion of infected memory B cell populations would 
allow for the establishment of this pool for EBV persistence26. Since the germinal center model 
is based on the cross-sectional analysis of EBV latency patterns in B cell differentiation stages 
and not fate mapping of latency III infected cells, establishment of latency 0 outside of germinal 
centers cannot be completely excluded. Along these lines, LCLs do not automatically 
differentiate into memory B cells with latency 0. 
 With the advent of recombinant EBV technology55, it has become possible to delete 
genes from the EBV genome and compromise complete B cell transformation and latency III 
gene expression. This allows for the investigation if then all other latency programs are also 
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abolished. This was recently queried using EBV deficient in EBNA3A and EBNA3C. As 
discussed above, these are essential latent EBV gene products that rescue EBV infected cells 
from cell death that is induced by EBNA2-driven proliferation43. Indeed, it is quite difficult to 
establish EBNA3A deficient LCLs56, and BIM as well as p16INK4a expression arrest proliferation 
of EBNA3C deficient LCLs57,58. Despite this, p16INK4a overexpression and a block in complete 
EBV latency III protein expression with LMP1 and LMP2, EBNA3A or EBNA3C deficient EBV 
establishes persistence in mice with reconstituted human immune system components (HIS 
mice)22. This persistence was associated with EBNA2-driven  proliferation during the first month 
of infection, which then, switched to EBV latency 0 persistence with only non-translated EBER 
expression after three months22. The observed absence of EBV latency III seems to be caused 
by a combination of EBNA3A or EBNA3C deficiency and immune control of rare completely 
virus transformed B cells, because in a HIS mouse model with less immunocompetence, LMP-
expressing EBNA3C-negative lymphomas can be observed at lower frequency compared to 
wild-type EBV infection59. These findings suggest that EBV persistence might be achieved with 
minimal or no EBV latency III infection. This points to an alternative route to EBV latency 0 
(Figure 1). Nevertheless, the combination of both the germinal center and the persistence 
without transformation pathways might render access to the memory B cell compartment for 
EBV more robust in humans, whose immune responses most likely pose greater obstacles to 
EBV persistence than those of HIS mice. 
 The observed EBNA2-driven proliferation prior to EBV latency 0 persistence points 
towards a distinct stage of B cell infection by EBV from which persistence might develop. 
Indeed, EBV gene expression is orchestrated during the first three weeks of B cell infection by 
EBV, as has been established by in vitro infection studies. Immediately after infection, the two 
viral BCL2 homologues BHRF1 and BALF1, which are usually considered lytic EBV gene 
products, are transiently expressed to prevent apoptosis60 (Figure 2). EBNA2 then starts driving 
proliferation of the infected B cells within the first three days through MYC expression among 
other factors61. The resulting rapid cell division (8–10h doubling time) activates the DNA 
damage response61 with an increase in BIM and p16INK4a tumor suppressor gene expression, 
which is inhibited by EBNA3C and to a lesser extent EBNA3A57,58,62. The pro-proliferative and 
anti-apoptotic gene expression programs induced by EBNA2, EBNA3A and EBNA3C dominate 
the first two weeks of B cell infection by EBV and are to a large extent regulated by viral 
superenhancers that are targeted by the viral nuclear antigens63,64. This infection program is 
also called latency IIb65,66 and has been observed in infectious mononucleosis and post-
transplant lymphoproliferative disease patients67,68. Only after two to three weeks are the LMPs 
Christian Münz  9 
sufficiently expressed to exert their pro-proliferative (LMP1) and anti-apoptotic (LMP1 and 
LMP2) functions69, resulting in complete EBV latency III expression with an LCL doubling time of 
24h. This time period is also needed for epigenetic modifications of the viral episome as a 
prerequisite of lytic EBV replication13. Therefore, between the 3 days of EBNA2 expression and 
the 2–3 weeks of LMP1 expression, EBV infected B cells might exit this latency III program into 
latency 0 persistence (Figure 2) in the absence of EBNA3C and to a lesser extent EBNA3A. 
This might allow the establishment of latent EBV infection for the priming of protective immune 
responses without the threat of overt lymphomagenesis. 
 
Oncogenesis with lytic replication  
Recent evidence suggests that latent EBV infection, especially latency III, is not the only 
contribution of this tumor virus to its associated malignancies. It was observed that BZLF1 
deficient EBV causes fewer B cell lymphomas in HIS mice23,70 (Figure 3). BZLF1 is the 
immediate early transcription factor for the activation of lytic EBV replication71. Is this 
observation just due to an increased viral titer or is there a novel oncogenic effect of lytic cycle 
genes? In these studies, early lytic EBV gene expression was primarily observed in the absence 
of late structural EBV proteins. This early lytic EBV gene expression includes the immediate 
early transcription factors BZLF1 and BRLF1, as well as proteins for viral DNA replication, 
immune evasins and anti-apoptotic proteins71. This is a fairly common observation, with often 
less than half of the BZLF1 and BRLF1 expressing cells progressing to complete lytic EBV 
replication32,72. Accordingly, LCLs deficient in the catalytic DNA polymerase subunit BALF5 
caused lymphomas more efficiently in immunodeficient mice73. Thus, it is most likely not 
increased B cell infection due to infectious EBV particle production, but rather a conditioning of 
the tumor microenvironment by abortive early lytic EBV replication that is responsible for the 
observed increased tumorigenesis (Figure 4). Along these lines, it was observed that more 
TNF-, CCL5 and IL-10 are produced by LCLs with higher levels of spontaneous lytic EBV 
reactivation74. These might inhibit the immune control by cytotoxic lymphocytes and recruit 
immunosuppressive myeloid cells75. Indeed, monocytes attracted by CCL5 into the Hodgkin’s 
lymphoma microenvironment support tumor growth in a xenograft model through their immune 
suppressive activities76. Contrary to loss of BZLF1, mutations in three suppressive elements of 
the BZLF1 promotor renders the respective EBV more lytic77. This ZV, ZV  and ZIIR triple 
mutant presents with increased lymphoma formation in HIS mice78 (Figure 3). Furthermore, a 
natural variant of the BZLF1 promoter was found in EBV viruses that are more often associated 
with nasopharyngeal carcinoma, EBV positive gastric carcinoma, Burkitt’s lymphoma and EBV-
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positive B cell lymphomas of individuals with AIDS79 (Figure 5). This BZLF1 promotor V3 variant 
demonstrates elevated induction of lytic EBV replication upon B cell receptor cross-linking or 
treatment of EBV infected cells with ionomycin, which stimulates the transcription factor NFAT. 
Indeed, the variation in the BZLF1 V3 promotor generates a NFAT binding side and the 
increased lytic replication can be blocked with the NFAT inhibitor cyclosporin. In addition to 
polymorphisms in the BZLF1 promotor, polymorphisms in the BZLF1 gene might also account 
for higher lytic EBV replication. Along these lines, the M81 EBV strain isolated from a 
nasopharyngeal carcinoma sample and three EBV isolates from gastric carcinomas induced 
increased spontaneous lytic EBV replication in B cells and epithelial cells80,81. M81 BZLF1, but 
not BZLF1 from EBV B95-8 that was isolated from an American individual with infectious 
mononucleosis, was able to induce this elevated lytic replication in the M81 EBV background, 
when provided in trans80. Thus, BZLF1 activity and the resulting early lytic EBV replication might 
condition the microenvironment for increased EBV-associated tumor formation.  
 A role for lytic EBV replication in EBV-associated tumor formation is further 
substantiated by deletions in EBV BART miRNAs, which were found to be enriched in EBV-
associated NK/T cell and diffuse large B cell lymphomas73 (Figure 3). These viruses are thought 
to promote higher levels of lytic EBV replication due to up-regulation of BZLF1 and BRLF1 
expression that are suppressed by one of the BART miRNAs82. The increased lytic replication 
might also contribute to circulating cell-free plasma EBV DNA loads, which are indicative of 
EBV-associated tumors in a variety of clinical settings83. This plasma viral load, rather than 
peripheral blood cell-associated EBV titers, have been found to correlate with nasopharyngeal 
carcinoma84, post-transplant lymphoproliferative disease85, diffuse large B cell lymphoma86, 
NK/T cell lymphomas87 and Hodgkin’s lymphoma88. The risk for Hodgkin’s lymphoma is also 
increased following primary EBV acquisition with infectious mononucleosis89-91. Infectious 
mononucleosis is characterized by elevated virus shedding into the saliva, high antibody titers 
against structural EBV proteins and massive expansion of lytic EBV antigen specific CD8+ T 
cells92 (Figure 5). These are all parameters of elevated lytic EBV replication and, thus, inefficient 
immune control of productive infectious viral particle production might contribute to the 
increased risk for Hodgkin’s lymphoma after infectious mononucleosis. Finally, EBV-associated 
post-transplant central nervous system lymphoma was cured by pharmacological inhibition of 
lytic EBV replication in a small number of individuals using a combination of Zidovudine, 
Rituximab and Dexamethasone93. Altogether, lytic EBV replication increases EBV-associated 
lymphomagenesis in preclinical in vivo models, virus strains with increased lytic EBV replication 
are enriched in EBV-associated malignancies and plasma viral loads correlate with some of 
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these diseases. Moreover,  inefficiently controlled lytic replication predisposes for Hodgkin’s 
lymphoma and in one EBV-associated tumor setting, inhibition of lytic EBV replication seems to 
have been therapeutically beneficial for the affected patients. Thus, lytic EBV replication might 
contribute to virus-associated tumorigenesis, possibly by conditioning the tumor 
microenvironment.  
 
Non-translated RNAs and tumorigenesis  
The non-translated RNAs expressed by EBV include the two EBERs and ~44 miRNAs25. 
Originally, both were suggested to promote EBV-driven tumorigenesis94-99. By contrast, and as 
discussed above, viruses with deletions in some of the BART miRNAs were found to be 
associated with diffuse large B cell and NK/T cell lymphomas73. This region in which deletions 
were found contains 22 pre-miRNAs and an additional three are located adjacent to the viral 
BHRF1 gene encoding a BCL2 homologue25 (Figure 6). The resulting ~44 miRNAs are grouped 
into either BHRF1 or BART miRNAs. The BHRF1 miRNAs are expressed during EBV latency III 
infection and its associated tumors, and two of the three pre-miRNAs are expressed during lytic 
EBV replication100,101 (Figure 1). By contrast, the BART miRNAs are expressed in all EBV 
infection programs, including EBV latency I and II, albeit at lower levels during latency I101,102. In 
addition to the regulation of lytic replication via down-regulation of BZLF1 and BRLF1 by BART 
miRNAs82, they have also been described to limit EBNA2, LMP1 and LMP2 expression103-106. In 
addition, BHRF1 miRNAs optimize the timing of EBNA-LP and BHRF1 expression for optimal B 
cell transformation107,108 and suppress sumoylation that is required for efficient lytic replication 
induction109. Finally, both BART and BHRF1 miRNAs attenuate B cell receptor signaling and 
thereby desensitize infected B cells to lytic EBV replication induction110. Therefore, both BART 
and BHRF1 miRNAs contribute to suppression of lytic EBV replication and optimize B cell 
transformation by EBV96,97.  
The B95-8 strain of EBV4,5 lacks many of the BART miRNAs but readily transforms 
human B cells, and viruses with deletions in the same region are enriched in diffuse large B cell 
lymphomas73. Along these lines, complete loss of all BART miRNAs from the B95-8 virus does 
not significantly alter its infection in HIS mice111. By contrast, loss of BHRF1 miRNAs either 
alone or in addition to BART miRNA deletion attenuates B95-8 EBV infection in HIS mice99,111. 
Interestingly, BHRF1 miRNAs are not necessary for B cell transformation, but the contribution of 
these miRNAs to immune escape seems to be crucial for the in vivo phenotype in HIS mice 
(Figures 4 and 6). Depletion of CD8+ T cells restores viral loads and tumorigenicity of miRNA 
deficient EBV111. Along these lines, BHRF1 miRNAs target CXCL11, which encodes a 
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chemokine that attracts CD8+ T cells via the CXCR3 chemokine receptor into sites of 
inflammation and tumorigenesis112,113. Furthermore, they also down-regulate the transporter 
associated with antigen processing (TAP) complex that is required for antigenic peptide import 
into the endoplasmic reticulum and loading onto MHC class I molecules for CD8+ T cell 
recognition114. In particular, TAP2 levels are down-regulated by BHRF1 miRNAs, which also 
destabilizes TAP1 levels and results in lower surface expression of some MHC class I 
molecules as well as diminished recognition of miRNA deficient LCLs by EBV-specific CD8+ T 
cell clones111,114. Thus, both BART and BHRF1 miRNAs of EBV optimize virus-mediated B cell 
transformation and block lytic replication, but BHRF1 miRNAs also promote immune escape 
from CD8+ T cell responses. This later function seems dominant in vivo during EBV infection of 
HIS mice, because CD8+ T cell depletion restores viral loads and tumorigenesis of miRNA 
deficient EBV. 
 Similar to BART miRNAs, EBERs are highly expressed in all EBV infection programs25. 
They are the most abundant viral transcripts with more than one million copies per EBV infected 
cell115. Due to their high abundance, in situ hybridization against EBERs still constitutes the gold 
standard for detecting EBV infected cells. In contrast to the miRNAs, they are confined to the 
nucleus and seem to interact with various RNA binding proteins, including La and L22115-117. 
Similar to BART miRNAs, EBERs seem to optimize B cell transformation by EBV, but possibly 
only in certain EBV strains94,118-120. Transgenic overexpression of EBERs leads to 
lymphoproliferations and less frequently B cell lymphomas95. However, EBER deficient B95-8 
EBV infection in HIS mice did not alter viral loads or tumorigenesis121. Thus, as for BART 
miRNAs, EBERs seem to improve B cell transformation, but their absence does not significantly 
alter EBV infection and tumorigenesis in HIS mice.  
 In summary, miRNA and EBER deficient viruses have helped reveal the immune escape 
function of the BHRF1 miRNA cluster and show that BART miRNA and EBER deficiency seems 
to have little impact on EBV infection and immune control in HIS mice. This is consistent with 
BART miRNAs being often partially deleted in EBV isolates. By contrast, the conservation and 
high expression of EBERs among all EBV viruses remains enigmatic. 
 
[H1] Conclusions  
Recent studies have changed our view on the tumorigenesis of the most common human tumor 
virus, namely EBV. As outlined in this Review, complete B cell transformation does not seem to 
be a prerequisite for EBV persistence, lytic EBV proteins play a role during virus associated 
tumorigenesis and viral miRNAs serve an important immune escape function during infection. 
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The contribution of lytic EBV antigen expression to virus-induced lymphoma and carcinoma 
formation reveal similarities to Kaposi sarcoma-associated herpesvirus (KSHV; also known as 
human herpesvirus 8 (HHV8)), the other oncogenic human -herpesvirus122. Some of the KSHV-
associated malignancies, like Kaposi sarcoma, seem to depend on lytic replication of this 
virus123. Targeting of early lytic antigen expression might provide a promising novel strategy for 
the treatment of both EBV and KSHV associated tumors124. 
 These three new characteristics of EBV associated lymphomas and carcinomas might 
also suggest mechanisms to attenuate and render EBV more immunogenic for vaccination. An 
EBNA3C, BZLF1 and miRNA deficient virus (3CZmiR EBV) might combine minimal 
oncogenicity with increased CD8+ T cell recognition. Such a virus would allow for EBNA2-
dependent viral antigen expression but compromise anti-apoptotic EBNA3C expression as well 
as the downstream pro-proliferative LMP1 and anti-apoptotic LMP1 and LMP2 functions. 
Furthermore, it would remove any tumor promoting early lytic EBV protein expression. Finally, 
such an 3CZmiR EBV would make the expressed EBV antigens (presumably EBNA1, EBNA2, 
EBNA3A, EBNA3B and EBNA-LP) more visible to CD8+ T cells due to efficient antigen 
processing for MHC class I presentation and attraction of these T cells into the tumor 
microenvironment through the CXCR3 ligands CXCL9, CXCL10 (both EBNA3B-driven) and 
CXCL11 (no longer inhibited by BHRF1 miRNAs). The strong dependency on cytotoxic 
lymphocytes, including the T cells that such an attenuated EBV would elicit for natural immunity 
to EBV125, has so far made it difficult to develop vaccines against this virus. Most of the vaccines 
currently in use mainly elicit protective antibody responses and the use of EBV itself, even in an 
attenuated form (as has been used for the vaccination against the varicella zoster -
herpesvirus126), has been considered too risky due to the oncogenic potential of EBV. 
Accordingly, new vaccination strategies that are being explored are either based on 
recombinant viral vectors that elicit EBV-specific immune control by cytotoxic lymphocyte 
populations127, or are based on novel recombinant viral glycoprotein formulations that stimulate 
more potent EBV-specific antibody responses than those usually observed in healthy EBV 
carriers128-130. Irrespective of the efficacy of these new EBV vaccine candidates, a better 
understanding of EBV-driven cellular transformation and its immune control, which has in part 
emerged from the use of HIS mice as a preclinical in vivo model for this virus, should allow us to 
more efficiently interfere with EBV pathologies and also to refine EBV-specific vaccination 
strategies in the future. 
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Glossary terms 
 
Latency: virus persistence without virion production. 
Abortive lytic replication: early lytic viral gene expression without virion production. 
EBNA: Epstein–Barr virus nuclear antigen that is expressed during latent infection with 
oncogenic function. 
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LMP: Epstein–Barr virus encoded latent membrane protein that mimics signals that B cells have 
to receive in germinal centers for their survival and that contribute to viral oncogenesis. 
BZLF1: An immediate early lytic transcription factor that initiates lytic EBV replication from fully 
methylated viral DNA. 
 
Box 1: Clinical aspects of Epstein–Barr virus infection 
Epstein–Barr virus (EBV) is a WHO class I carcinogen131,132. It is estimated to cause 1–2% of all 
tumors in humans and ~200,000 new cancers per year133. Epithelial cancers like 
nasopharyngeal carcinoma and the ~10% of gastric carcinoma that are associated with EBV 
outnumber in incidence the EBV-associated lymphomas, which include Burkitt’s, Hodgkin’s, 
diffuse large B cell, NK/T cell and primary effusion lymphoma6,10. The B cell lymphomas emerge 
either spontaneously or during immune suppression, for example, during HIV-1 co-infection134. 
Although B cell depleting therapy and EBV specific T cell transfer can often therapeutically 
address EBV associated B cell lymphomas135, the therapeutic options for the epithelial cell 
cancers, especially at an advanced disease stage, are often limited. However, adoptive EBV 
specific T cell transfer is currently being explored for nasopharyngeal carcinoma136. For 
Hodgkin’s lymphoma, immune checkpoint blockade of PD-1 has also shown promising 
results137. Thus, EBV causes a variety of tumors due to failing immune control, some of which 
can be treated by restoring EBV specific T cell responses by adoptive transfer or blocking of 
inhibitory receptors. 
 By contrast, other EBV associated pathologies seem to result from too strong immune 
responses, which do not efficiently clear the virus. These immunopathologies include 
symptomatic primary EBV infection or infectious mononucleosis, EBV associated 
hemophagocytic lymphohistiocytosis (HLH) and possibly the autoimmune disease multiple 
sclerosis7,125,138. The symptoms of these diseases might be caused by the efficient stimulation of 
T cell mediated cytokine production by latently EBV infected B cells, in the absence of efficient 
cytotoxic elimination of infected cells. In multiple sclerosis, adoptive transfer of EBV specific T 
cells has been tried to eliminate this T cell stimulating EBV reservoir, with promising initial 
results139. In addition, vaccination against EBV will probably be further explored in EBV 
seronegative adolescents to prevent infectious mononucleosis140. 
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Figure legends 
Figure 1: Models of latent Epstein–Barr virus infection to reach viral persistence. 
Epstein–Barr virus (EBV) persists in circulating memory B cells without viral protein expression 
(latency 0). Only during homeostatic proliferation of these memory B cells is EBNA1 transiently 
expressed. After transfer across the mucosal epithelium from the saliva, the virus infects B cells 
in secondary lymphoid tissues like the tonsils. This infection leads to EBNA2-dependent 
proliferation of infected cells. Infected memory B cells may differentiate directly into latency 0 
after infection. Alternatively, it drives naïve B cells into full latency III (during which EBNA1, 
EBNA2, EBNA3A-C, EBNA-LP, LMP1 and LMP2 are expressed) transformation and this 
activation leads to their differentiation via latency IIa (during which EBNA1, LMP1 and LMP2 are 
expressed) expressing germinal center B cells to latency 0 memory B cells. This germinal 
center differentiation pathway is thought to provide premalignant precursors of the EBV-
associated diffuse large B cell lymphoma, Hodgkin’s lymphoma and Burkitt’s lymphoma. From 
circulating memory B cells, EBV reactivates lytic replication upon plasma cell differentiation and 
primary effusion lymphomas (PELs) are EBV associated plasmacytomas. This lytic reactivation 
most likely allows epithelial cell infection from the basolateral side for efficient shedding into the 
saliva and virus transmission. This epithelial cell infection gives rise to EBV associated 
carcinomas, for example, nasopharyngeal carcinoma (NPC). Expression of the viral non-
translated RNAs (EBERs, BART and BHRF1 miRNAs) is also depicted. 
 
Figure 2: Persistence without transformation. 
Upon B cell infection by Epstein–Barr virus (EBV) the viral BCL2 homologues BHRF1 and 
BALF1 are expressed during the first three days to ensure survival of the host cell. Then EBNA2 
drives cellular proliferation through the viral oncogene MYC and cooperates with EBNA-LP for 
LMP1 and LMP2 expression. The resulting apoptosis induction by p16INK4a and BIM is blocked 
by EBNA3A and EBNA3C. After several weeks, LMP1 and LMP2 expression activates NF-B 
transcription and this completes B cell transformation. EBV persistence in memory B cells 
without viral gene expression can be reached after transformation through differentiation in 
germinal centers, or directly from the EBNA2-induced B cell proliferation outside of germinal 
centers. 
 
Figure 3: Oncogenesis with lytic replication. 
Conditions that lead to higher BZLF1 expression and thus induction of lytic Epstein–Barr virus 
(EBV) replication increase virus driven tumorigenesis. These include elevated BZLF1 
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expression due to loss of BART miRNA-mediated suppression (BART), BZLF1 promotors that 
increase expression (ZV, ZV , ZIIR and V3) or polymorphisms in the BZLF1 coding sequence 
(M81 BZLF1). Suppression of BZLF1 expression (BZLF1) inhibits virus induced lymphoma 
formation. Lytic replication driven by the BZLF1 gene of the B95-8 virus isolate causes an 
intermediary phenotype. 
 
Figure 4: Potential functions of lytic EBV antigens and non-translated RNAs during Epstein–
Barr virus driven tumor formation. 
Early, most likely abortive lytic Epstein–Barr virus (EBV) replication, might condition the tumor 
microenvironment for EBV associated malignancies through attraction of monocytes via CCL5 
and their differentiation into immune suppressive tumor associated macrophages (TAMs). 
These TAMs and early lytic EBV replication seem to promote IL-10 production to suppress 
protective cytotoxic lymphocyte responses, including CD8+ T cells. In addition, EBV encoded 
miRNAs compromise the attraction of these cytotoxic lymphocytes into the tumor 
microenvironment by down-regulating CXCL11 expression and also inhibit antigen presentation 
on MHC class I molecules to these CD8+ T cells. Thus, early lytic EBV replication and viral 
miRNAs seem to collaborate to render the microenvironment of EBV associated malignancies 
immune suppressive. 
 
Figure 5: Lytic replication in clinical manifestations of Epstein–Barr virus infection. 
The association of varying degrees of lytic Epstein–Barr virus (EBV) replication with EBV 
associated malignancies (lymphomas and carcinomas), overt lytic EBV replication in the tongue 
epithelium (oral hairy leukoplakia) and immune pathologies (infectious mononucleosis). These 
associations are based on the enrichment of viral strains with enhanced lytic replication with the 
respective tumors, detection of serum viral loads in affected patients and decreased 
tumorigenesis of certain lymphomas (post-transplant lymphoproliferative disease, diffuse large 
B cell lymphoma and primary effusion lymphoma) upon lytic replication-incompetent EBV 
infection of preclinical in vivo models.  
 
Figure 6: Non-translated RNAs in the Epstein–Barr virus genome. 
Schematic depiction of the 172 kb Epstein–Barr virus (EBV) genome showing the location of the 
two Epstein–Barr virus encoded small RNAs (EBERs), the BHRF1 (BHRF1 miR) and BART 
miRNAs (BART miR). The locations of the latent EBV genes encoding EBNA-LP, EBNA2, 
EBNA3A-3C and EBNA1, as well as LMP1 and LMP2 are also shown. The loci of the viral BCL2 
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homologues BHRF1 and BALF1, as well as the immediate early transcription factors for lytic 
EBV replication, BZLF1 and BRLF1, are depicted.  
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